Trial Profile
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone-Sensitive Prostate Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 01 Mar 2024
Price :
$35
*
At a glance
- Drugs Orteronel (Primary) ; Bicalutamide; Leuprorelin; LHRH receptor agonists
- Indications Prostate cancer
- Focus Therapeutic Use
- 27 Jan 2024 Results of Patient level data from this study analyzing Baseline bone pain as a prognostic marker for survival for men with metastatic hormone-sensitive prostate cancer, presented at the 2024 Genitourinary Cancers Symposium
- 23 Jan 2024 Results published in a 2024 ASCO Daily News and 2024 ASCO GENITOURINARY CANCERS SYMPOSIUM media release.
- 23 Jan 2024 According to ASCO Daily News and 2024 ASCO GENITOURINARY CANCERS SYMPOSIUM media release, Patient-level data from the SWOG-1216 trial, which included newly diagnosed patients with metastatic hormone-sensitive prostate cancer, to be presented during the 2024 ASCO Genitourinary Cancers Symposium.